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ABSTRACT 
 
The present thesis is an overview of the Supplementary Protection Certificate (‘SPC’) 
regime in the European Union (‘EU’) and its application in the pharmaceutical industry. 
During the past years the Court of Justice of the European Union (‘CJEU’) has been 
particularly active and has clarified a number of highly controversial legal ambiguities 
with respect to SPCs including paediatric extensions. In the light of the CJEU case-law, 
this thesis analyses the relevant legal provisions and discusses their rationale. 
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A. INTRODUCTION 
Companies across Europe are meeting health challenges head on by investing in time, 
talent, and materials. European law has long protected these endeavors through the 
intellectual property (IP) regime. This legislation has been very important in creating 
and sustaining the technological sectors, especially those where innovation is very 
costly, such as the pharmaceutical sector. The investment in the research and 
development (‘R&D’) of pharmaceutical products, which play a decisive role in the 
continuing improvement of public health, is protectable by means of patents. The patent 
regime in the pharmaceutical sector is complemented by a special IP regime which 
provides for supplementary patent protection on a timely basis under specific 
circumstances, i.e. the SPC regime.  
This special IP regime has direct effect in the Member States of the European Union 
(‘EU’), which means that the decisive forum for its interpretation and ultimate arbiter 
is the CJEU 1 . The latter is presented with the increasingly challenging task of 
interpreting the present legislation in a clear, coherent and fair manner. Its judgments 
provide patent offices and national courts with important guidance on the application 
of the SPC regime. The number of questions referred to the CJEU for interpretation of 
the SPC regime indicates its practical significance for applicants, who wish to make use 
of the possibilities for obtaining extended patent protection for their pharmaceutical 
products. Therefore, the following analysis is based on the legislation, along with the 
respective CJEU judgments interpreting it.  
More concretely, a basic overview of the patent system in general, and the 
pharmaceutical patents in particular, at a EU level, is a beginning point to explore the 
special IP regime in the pharmaceutical industry. In this context, the first part presents 
the European patent system and the peculiarity of patents on pharmaceutical products. 
Then, the next chapter provides an overview of the SPC regime and its rationale, whilst 
presenting the core provisions of this regime. Reference is made to the products 
concerned, the extent of the SPC protection, the way of obtaining a SPC, with focus on 
the conditions and the application procedure, the duration of the SPC, and the relevant 
                                                          
1  Westerlund L., Preliminary Ruling of the Court of Justice of the European Union in Neurim 
Pharmaceuticals (1991) Ltd. v. Comptroller of Patents on Supplementary Protection Certificates in 
Europe, 31 Biotechnology Law Report, Number 6, 2012, 566. 
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transitional provisions. Finally, the last part of the present thesis recapitulates the core 
CJEU judgments dealing with the SPC regime and includes a few final remarks. 
 
B. EUROPEAN PATENT LAW AND THE PHARMACEUTICAL 
SECTOR 
 
I. PATENTS AND THEIR RATIONALE 
There are two distinct rationales that might be given for patents2: the one justifies 
patents as recognition of the inventor’s creativity and the other justifies patents as 
means to enhance innovation. In either case, patent rights can be understood as a 
definition of property rights with regard to new technological knowledge for a limited 
time span3. During the life of the patent, its proprietor has the right to exclusively 
exploit the protected specific knowledge economically, whilst other market participants 
can only gain access to the protected technical knowledge on the condition of approval 
of the owner, usually obtained by means of license agreements4. 
II. LEGAL INSTRUMENTS 
A first legal instrument is the Paris Convention for the protection of industrial property 
(‘PC’) 5 which is a multilateral treaty, applying not only to patents, but also to industrial 
property in the widest sense. It provides protection based on national treatment and 
international property rights. National treatment requires that each Contracting State 
must grant the same protection to nationals of other Contracting States that it grants to 
its own nationals6 . The priority right 7  means that, on the basis of a regular first 
application filed in one of the Contracting States, the applicant may, within a certain 
period of time, apply for protection in any of the other Contracting States. These 
subsequent applications will be regarded as if they had been filed on the same day as 
the first application. In other words, they will have priority over applications filed by 
                                                          
2 Barton J.H./Ezekie J.E., The patents-Based Pharmaceutical Development Process, JAMA, October 26, 
2005, Vol. 294, No. 16, 2076. 
3 Seckelmann M., From the Paris Convention (1883) to the TRIPS Agreement (1994): the history of the 
international patent agreements as a history of propertisation?, Journal der Juristischen Zeitgeschichte. 
Volume 14, Issue 1, 41. 
4 Seckelmann M., (n 3) 41. 
5 The PC, concluded in 1883, was revised at Brussels in 1900, at Washington in 1911, at The Hague in 
1925, at London in 1934, at Lisbon in 1958 and at Stockholm in 1967, and was amended in 1979. 
6 Article 2(1) PC.  
7 Article 4 PC. 
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others during the said period of time for the same invention, utility model, mark or 
industrial design. However, the PC does not provide for centralized filing or registration 
and concomitantly, the registrant must use the judicial system of the alleged infringer’s 
country to enforce his rights8. 
In 1967, Members of the PC created the World Intellectual Property Organization 
(‘WIPO Convention’), which aims to promote the international protection of IP and to 
administer various international agreements through cooperation among States 9 . 
During its first 20 years, WIPO was a strong force for administration of international 
conventions, but ineffective as a catalyst in the movement towards harmonization10. 
Dissatisfied with the progress being made by WIPO on substantive and enforcement 
issues for international IP, the U.S. and other nations turned to the 1994 negotiations 
regarding the General Agreement on Tariffs and Trade (‘GATT’) for the purpose, the 
result of which was the Trade Related Aspects of IPRs agreement (‘TRIPS’)11. TRIPS, 
which is an integral part of the Agreement establishing the World Trade Organization 
(‘WTO’), covers not only patents, but also all the other main areas of IP rights (‘IPRs’). 
It lays down the minimum substantive standards of protection that should be provided 
for in each of these areas of IP as well as the procedures and remedies available, so that 
right holders can enforce their rights effectively12. The crucial point that distinguishes 
TRIPS from the PC is that the former set out a mere moral obligation to set up a patent 
legislation in accordance with its principles, whereas TRIPS departed from this 
principle and set out a basic reciprocity13. 
Based on the PC14, several agreements were concluded. One of them is the European 
Patent Convention (‘EPC’). The latter is a regional international convention outside the 
EU legal order with 38 Member States, harmonising the requirements to get a patent 
and granting a bundle of national rights 15  designated by the applicant 16 . More 
concretely, Article 64(1) EPC states that a European patent shall confer from the date 
                                                          
8 Bravo G., From Paris Convention to TRIPs: A Brief History, 12 J. Contemp. Legal Issues, 2001-2002, 
446. 
9 Article 3 WIPO Convention. 
10 Bravo G., (n 8) 447. 
11 Bravo G., (n 8) 448. 
12 Otten A., WHO Drug Information, 1998, Vol. 12, No. 4, 211. 
13 Seckelmann M., (n 3) 56. 
14 Special agreement under Article 19 PC. 
15 Article 2(2) EPC. 
16 Article 79 EPC. 
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of publication of the mention of its grant, in each Contracting State in respect of which 
it is granted, the same rights as would be conferred by a national patent granted in that 
State. In addition, Article 64(3) EPC notes that any infringement of a European patent 
shall be dealt with by national law. Further, Article 138(1) EPC states that a European 
patent may only be revoked under the law of a Contracting State, with effect for its 
territory. Another agreement introduces, based on PC, the Patent Cooporation Treaty 
(‘PCT’) 17 .The PCT makes it possible to seek patent protection for an invention 
simultaneously in each of a large number of countries by filing an "international" patent 
application. Such an application may be filed by anyone who is a national or resident 
of a Contracting State. It may generally be filed with the national patent office of the 
Contracting State of which the applicant is a national or resident or, at the applicant's 
option, with the International Bureau of WIPO in Geneva. If the applicant is a national 
or resident of a Contracting State which is party to the EPC the international application 
may also be filed with the EPO. In addition, the Patent Law Treaty (PLT) was adopted 
in 2000 with the aim of harmonizing and streamlining formal procedures with respect 
to national and regional patent applications and patents and making such procedures 
more user friendly. With the significant exception of filing date requirements, the PLT 
provides the maximum sets of requirements the office of a Contracting Party may apply. 
Aside from the above, there are also several legal instruments at EU level, e.g. Directive 
98/44 on biotechnological inventions 18 , Regulation 469/2009 concerning the 
supplementary protection certificate for medicinal products 19 , Regulation 1610/96 
concerning the creation of a supplementary protection certificate for plant protection 
products 20 , Regulation 1901/2006 on medicinal products for paediatric use 21 , 
Regulation 2100/94 on plant variety protection22, Regulations 1257/2012 implementing 
                                                          
17 The PCT was concluded in 1970, amended in 1979, and modified in 1984 and 2001. 
18 DIRECTIVE 98/44/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 July 1998 on the 
legal protection of biotechnological inventions, OJ L 213/13, 30.7.98. 
19 REGULATION (EC) No 469/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 May 
2009 concerning the supplementary protection certificate for medicinal products, OJ L 152/1, 
16.6.2009. 
20 REGULATION (EC) No 1610/96 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 23 July 1996 
concerning the creation of a supplementary protection certificate for plant protection products, OJ L 
198/30, 8.8.96. 
21  REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 
December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, 
Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, OJ L 378/1, 27.12.2006. 
22 COUNCIL REGULATION (EC) No 2100/94 of 27 July 1994 on Community plant variety rights, OJ L 
227/1, 1.1.94. 
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enhanced cooperation in the area of the creation of unitary patent protection23 and 
1260/2012 implementing enhanced cooperation in the area of the creation of unitary 
patent protection with regard to the applicable translation arrangements24. As for the 
enforcement of patents, while there is no European-wide patent, and thus, no ability to 
obtain a judgment enforceable across all of the EU, there is reciprocal enforcement of 
judgments within the EU25, by virtue of Regulation 1215/2012 on jurisdiction and 
recognition and enforcement of judgments in civil and commercial matters26. 
III. PATENT PROTECTION 
1. Conditions  
In order for an invention to be patentable, four requirements should be fulfilled, namely 
invention, novelty, inventive step, and industrial applicability27. Further requirement is 
that the applicant discloses the invention in a manner sufficiently clear and complete 
for the invention to be carried out as well as that the applicant indicates the best mode 
for carrying it out28. Disclosure is a key part of the social contract that the grant of a 
patent constitutes, since it makes publically available important technical information 
which may be of use to others in advancing technology in the area, even during the 
patent term, and ensures that, after expiry of the patent term, the invention truly falls 
into the public domain, because others have the necessary information to carry it out29. 
2. Subject matter 
European patents shall be granted for any inventions, in all fields of technology, 
provided that they meet the aforementioned patentability requirements30. In order to 
avoid monopolization of specific matters, the EPC provides for non-exhaustive list of 
                                                          
23 REGULATION (EU) No 1257/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 17 
December 2012 implementing enhanced cooperation in the area of the creation of unitary patent 
protection, OJ L 361/1, 31.12.2012. 
24  COUNCIL REGULATION (EU) No 1260/2012 of 17 December 2012 implementing enhanced 
cooperation in the area of the creation of unitary patent protection with regard to the applicable 
translation arrangements, OJ L 361/89, 31.12.2012. 
25 Blanchard A.M./Grill K./Steinberg J., A Practical Guide to IP Issues in the Pharmaceutical Industry, 
EIPR Practice Series, Book 2, 2007, 30-31. 
26 REGULATION (EU) No 1215/2012 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 12 
December 2012 on jurisdiction and the recognition and enforcement of judgments in civil and 
commercial matters, OJ L 351/1, 20.12.2012. 
27 Articles 52-57 EPC, 27(1) TRIPS. 
28 Article 83 EPC, 29(1) TRIPS. 
29 Otten A., (n 12) 211. 
30 Article 52(1) EPC, 27(1) TRIPS. 
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things which are not regarded as inventions31. Items on this list are all either abstract 
(eg discoveries, theories) and/or non-technical (ie address only human mind without 
using forces of nature) (eg aesthetic creations or presentations of information or 
computer programs). Thus, subject matter of patent protection are technical inventions 
with proven applicability to either products or processes32. 
3. Exceptions 
Patents may not be granted in respect of i) inventions, the prevention of the commercial 
exploitation of which is necessary to protect ordre public or morality, ii) diagnostic, 
therapeutic and surgical methods for the treatment of humans or animals, and iii) certain 
plant and animal inventions33. 
4. Scope 
The scope of patent protection is determined by the claims which should be interpreted 
on the basis of the description and the drawings34. By the patent is protected any product 
or process in which the characteristics of the claim are embodied. Patent claims 
comprise technical features and measures which can be interpreted in different ways, 
i.e. narrowly or broadly. The extent of the patent protection should not be defined in a 
strict, literal meaning of the wording used in the claims, nor should the claims serve 
only as a guideline and the actual protection conferred may extend to what the patent 
proprietor has contemplated. On the contrary, it is to be interpreted as defining a 
position between these extremes which combines a fair protection for the patent 
proprietor with a reasonable degree of legal certainty for third parties35. 
IV. PATENT RPOTECTION FOR PHARMACEUTICALS 
1. Pharmaceutical industry and innovation 
The development of a medicinal product is an enormously expensive process because 
of the high attrition rate of potential products as they proceed through laboratory, 
animal, and various human trials, as well as the high costs of trials needed for regulatory 
approval36. Current R&D costs in pharmaceutical industry are, namely, much higher 
                                                          
31 Article 52(2) EPC. 
32 EPO Cases T 1538/05, 28.08.2006, at [4]; T 154/04, 15.11.2006, at [8]; Seckelmann M., (n 3) 42. 
33 Article 53 EPC, 27(2),(3) TRIPS. 
34 EPC 69(1). 
35 Protocol on the Interpretation of Article 69 EPC. 
36 Barton J.H./Ezekie J.E., (n 2) 2076. 
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than most, if not all, other industries. As a Judge of the Court of Appeal of England and 
Wales states37: “It is no good finding a potential suitable molecule. Unless you spend 
the money and time to find out if it really works and is safe, it is no use”. Even higher 
than R&D costs is the promotional expenditure38 . Along with the high costs, the 
investment in pharmaceutical innovation entails high risk, since it is often the case that 
the research leads nowhere. Because of the high risk, pharmaceutical innovation does 
not only include products with new active pharmaceutical ingredients (APIs), but it 
includes also a large number of improvements or minor changes to existing drugs and 
the identification of new uses of known medicinal products39. Incremental innovation 
is often motivated by the objective of extending the commercial benefits derived from 
existing products, particularly when original patents expire and new patents may be 
used to prolong market exclusivity40. 
2. Pharmaceutical Patents 
A pharmaceutical invention is patentable, if it meets the aforementioned patentability 
criteria, which are the same in all technical fields. Given the nature of pharmaceutical 
industry’s research activities, which are dominated by profit-making objectives, they 
rely heavily on the acquisition and enforcement of patents41. It is a common ground that 
the higher the risk the more reward is needed to persuade the investors to put their 
money up42, and, as stated above, the nature of such an investment is risky. This means 
that without a reliable patent monopoly there is no incentive to invest43. If there is no 
IP protection for a new drug produced, companies essentially lose all economic 
incentive to further innovation and discovery because competitors can easily replicate 
the compounds for the same profit without the heavy financial investment. The EU 
Member States should provide such incentives, especially when it comes to 
pharmaceuticals, since they are responsible for providing health services and medical 
                                                          
37 Jacob R., Patents and Pharmaceuticals – a Paper given on 29th November at the Presentation of the 
Directorate-General of Competition’s Preliminary Report of the Pharma-sector inquiry, 3. 
38 Jacob R., (n 37) 4. 
39 Correa C.M., Ownership of knowledge – the role of patents in pharmaceutical R&D, Bulletin of the 
World Health Organization, October 2004, 82 (10), 785. 
40 Correa C.M., (n 42) 785. 
41 Correa C.M., (n 42) 786. 
42 Jacob R., (n 37) 4. 
43 Jacob R., (n 37) 3. 
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care within their territories44. It is the patent system, which provides such incentives, 
making thus, the advances in medicines possible.  
Indeed, pharmaceutical patents are a fundamental component to the success of the 
pharmaceutical industry. They play a crucial role in terms of stimulating developments 
of new drugs. In this sense, the pharmaceutical industry is very R&D-intensive45. A 
patent is granted for a drug’s novel chemical composition rather than its therapeutic 
properties46. Many pharmaceuticals receive patents despite their being functionally 
similar to existing drugs47. Patents are so valuable to the pharmaceutical industry, 
because in most cases the value of the patent is equivalent to the value of the product48. 
The pharmaceutical industry recovers its expenses through charging a high price for the 
drug based on exclusivity rights under a patent49. When the patent expires, the price 
normally decreases through competition with generic drugs50. Therefore, it is essential 
for pharmaceutical companies to maintain their patent rights. 
It should be noted, however, that a patent only gives an inventor the right to prevent 
others from using the patented invention. It says nothing about whether the product is 
safe for consumers and whether it can be supplied51. Patented pharmaceuticals still have 
to go through rigorous testing and approval before they can be put on the market. The 
effective length of the patent monopoly is not the same as the normal 20 years from the 
date of the application stated in patent law.  In particular, although the term of all patents 
is the same, i.e. 20 years from the application, in reality a new drug is unlikely to get 
this much as an effective patent term52. Reason for this is that companies, in order to 
                                                          
44 Article 152 of the Treaty on the Functioning of the European Union, OJ C 326/47, 26.10.2012. 
45 Brekke K.R./Straume O.R., Pharmaceutical Patents: Incentives for R&D or Marketing?, Discussion 
Paper 22/2005, 2, 
http://www.nhh.no/Admin/Public/DWSDownload.aspx?File=%2FFiles%2FFiler%2Finstitutter%2Fsam
%2FDiscussion+papers%2F2005%2F22.pdf  
46 Brekke K.R./Straume O.R., (n 39) 3-4. 
47 Brekke K.R./Straume O.R., (n 39) 3-4. 
48 BernIer K.J., Obviating the obvious? An appraisal of pharmaceutical patents, 10 J High Tech. L. 208 
2009-2010, 239-240. 
49 Barton J.H./Ezekie J.E., (n 2) 2076. 
50 Barton J.H./Ezekie J.E., (n 2) 2076. 
51 WTO OMC Factsheet, September 2006, 2, 
https://www.wto.org/english/tratop_e/trips_e/tripsfactsheet_pharma_2006_e.pdf  
52 Delcourt D., Public Health and preservation of economic competitiveness, Journal of Intellectual 
Property Law & Practice, 2009, Vol. 4, No. 6, 441. 
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preempt competitors, must apply for patents early in the development process, while 
marketing exclusivity occurs only after trials lead to regulatory approval53. 
 
C. THE SUPPLEMENTARY PROTECTION CERTIFICATE REGIME 
 
I. INTRODUCTION TO THE SUPPLEMENTARY PROTECTION 
CERTIFICATE REGULATION 
On average 9 and 11 years elapse between the patent application date and the day when 
a pharmaceutical is put on the market. This leaves an effective patent term of between 
9 and 11 years54. The relatively short effective patent term for pharmaceuticals began 
to be noticed during the 1980s, i.e. about 10 years after the authorities granting permits 
for the sale of pharmaceuticals began to make more and more exacting demands for 
clinical trials, which led to a reduction of the effective patent term55. Many areas around 
the world introduced statutes extending the patent term and providing supplementary 
protection for pharmaceuticals: the USA56 in 1984, Japan57 in 1987, Europe during the 
1990s, France58 and Italy59 in 1991. The interplay of the exclusive right conferred by 
patents to innovative pharmaceutical products and the regulatory rules for their 
marketing approval seemed to be solved in EU Member States which started to regulate 
this matter independently. This practice though, would lead the same pharmaceutical to 
be protected for different lengths of time in different EU countries60.  
This situation, which would be contrary to the basic principle of a common market, led 
the Commission to introduce Regulation (EEC) No 1768/92 61  providing for 
supplementary protection which came into force on 2 January 199362. The purpose 
behind this Regulation is to improve the protection of innovation in the pharmaceutical 
sector by ensuring that research based industry has market exclusivity of sufficient 
                                                          
53 Barton J.H./Ezekie J.E., (n 2) 2076. 
54 Domeij B., Pharmaceutical Patents in Europe, 2000, 196. 
55 Domeij B., (n 54) 196. 
56 Drug Price Competition and Patent Term Restoration Act of 1984. 
57 Japanese Statute No. 27/1987, which came into force on 1st January 1988.  
58 French Statute No. 91-1180/1991. 
59 Italian Statute No. 349/1991. 
60 Domeij B., (n 54) 196. 
61 COUNCIL REGULATION (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary 
protection certificate for medicinal products, OJ L 182/1, 2.7.92.  
62 Article 23. 
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length to permit recovery of the investments put into research63. Its content has been 
refined by CJEU case-law. More concretely, in Spain v Council64  the Regulation 
survived a challenge to its validity. The CJEU declared that neither Article 222 nor 
Article 36 of the Treaty reserves a power to regulate substantive patent law to the 
national legislature, to the exclusion of any Community action in the matter65. It follows 
that the Regulation was validly adopted66. In order for the effects of supplementary 
protection not to be delayed by many years, it was judged necessary for supplementary 
protection to be obtainable for pharmaceuticals which were already on the market when 
the Regulation came into force67. 
This Regulation was followed by Regulation (EC) 1610/1996 concerning SPCs for 
plant protection (‘PPR’)68, some rules of which are also valid, mutatis mutandis, for its 
interpretation. Furthermore, Regulation (EC) 1901/2006 concerning medicinal 
products for paediatric use (‘PUR’)69 introduced an extension of the SPC duration in 
specific cases. Regulation (EEC) No 1768/92 was repealed by Regulation (EC) No 
469/2009 (‘SPCR’) 70  which forms a new legal framework for SPCs, whilst 
encompassing the amendments by the PUR.  
II. ROLE 
The SPC regime allows patent owners to extend on a timely basis their exclusive rights 
upon expiration of the patent, thus mitigating the negative effects of lengthy 
administrative MAs71. The creation of the SPC does not in any way affect the substance 
of the rights of the holder of the basic patent, but it is rather a mechanism for correcting 
the shortcomings of the system for protecting pharmaceutical research, which arise 
from the need to obtain MA in order to make use of the innovation 72 . The SPC, 
therefore, delays the date from which the product in question comes into the public 
                                                          
63  Explanatory Memorandum on the Proposal for a COUNCIL REGULATION (EEC) concerning the 
creation of a supplementary protection certificate for medicinal products (COM (90) 101 final) at [2], 
[25]. 
64 C-350/92. 
65 C-350/92 at [22]. 
66 C-350/92 at [40]. 
67 Article 19 SPCR. 
68 (n 20). 
69 (n 21). 
70 (n 19). 
71 Porcuna de la Rosa F., “The extension of the exclusive right to pharmaceuticals under the European 
law: The Supplementary Protection Certificate”, Pharmaceuticals Policy and Law 13 (2011), 62. 
72 C-350/92 at [15].  
11 
 
domain and may be competitively marketed73. Since the SPCR establishes a system of 
protection supplementary to that granted by a basic patent, the SPC is ancillary to a 
previously granted national or European patent74. Based on this, it has been supported 
that the SPC is the natural extension of the basic patent75 and it does not create a new 
IPR76. Some take, also, the view that the SPC regime does not extend the patent term, 
but instead, it confers on patentees, by virtue of the SPCR and PPR, a separate right, 
the SPC77. The latter approach finds grounds on the Explanatory Memorandum for the 
SPCR which states that a SPC is a unique sui generis IPR conferring additional 
exclusivity for specific products covered by a patent upon expiry of that patent78. The 
reason for this approach lays in the fact that the SPC regime is a creature of the EU law, 
in contrast to patents, which in general are not, but are instead subject to the EPC, which 
is not an EU measure79, and which did not at the time of drafting the first SPCR admit 
the possibility of patent term extension80. 
III. PRODUCTS QUALIFYING FOR SUPPLEMENTARY 
PROTECTION  
1. Medicinal products 
Pursuant to Article 1 SPCR, the term ‘medicinal product’ is defined as any substance 
or combination of substances presented for treating or preventing disease in human 
beings or animals and any substance or combination of substances which may be 
administered to human beings or animals with a view to making a medical diagnosis or 
to restoring, correcting or modifying physiological functions in humans or in animals, 
and the term ‘product’ is defined as the active ingredient or combination of active 
ingredients of a medicinal product. A distinction is thus, made between ‘medicinal 
product’ and ‘product’. The latter term refers to the API or to the combination of APIs 
                                                          
73 Advocate General’s Opinion in C-431/04 at [35]. 
74 Advocate General’s Opinion in C-431/04 at [4]; Advocate General’s Opinion in C-66/09 at [19]. 
75 Advocate General’s Opinion in C-431/04 at [40]-[44]. 
76 C-350/92 at [27]. 
77 Cook T., The Court of Justice Recasts the EU Patent Term Extension System, Journal of Intellectual 
Property Rights, Vol 19, March 2014, 141; Storz U., Biopatent Law: Patent Strategies and Patent 
Management, Hübel A./Schmelcher T./Storz U., 2012, 28; Gassner U.M., Recent developments in the 
area of supplementary protection certificates, Pharmaceutical Policy and Law 16 (2014), 45. 
78 Explanatory Memorandum (n 63) at [9], [20], [31]. 
79 Cook T., (n 77) 141. 
80 The EPC was amended to permit patent terms of more than 20 years by the Act Revising Article 63 
EPC of 17.12.1991 which entered into force on 04.07.1997 (OJ EPO 1992, 1 ff). 
12 
 
of the pharmaceutical to which the first term refers81 . More concretely, medicinal 
products include products which are used therapeutically or prophylactically in animals 
or human beings82. In the case of diagnostic products, however, the provision requires 
that they are administered to animals or human beings83. This means that diagnostic 
equipment used in vitro, e.g. tests used for blood sampling, are not eligible for 
supplementary protection, whereas diagnostic products administered in vivo, e.g. X-ray 
contrast media, are eligible for SPC protection84. Whilst the categories of medicinal 
products that are eligible in principle for SPC protection are determined in the SPCR, 
the terms ‘active ingredient’ and ‘combination of active ingredients’ that form a 
‘product’ are not defined in the SPCR. Thus, the issue of what types of invention 
constitute a product within the meaning of the SPCR serving as a basis for a SPC, entails 
a little controversy. 
A first question which arises is whether an excipient which changes the behavior of an 
API can be considered itself as an API. The Explanatory Memorandum accompanying 
the European Commission’s ‘Proposal for a Council Regulation on the Creation of a 
Supplementary Certificate for the protection of Medicinal Products’ (‘Explanatory 
Memorandum’) clarifies that the term ‘product’ is to be understood in a narrow sense 
of product which means the active ingredient when applied to the chemical and 
pharmaceutical field85. The Advocate General (‘AG’) in MIT86 case answered the above 
question in the negative, staying in line with the strict interpretation of the term 
‘product’ that the Explanatory Memorandum suggests. More concretely, the AG stated 
that the concept of ‘active ingredient’ designates a substance, such as a chemical 
compound or a natural solution, with pharmacological or physiological properties on 
which the therapeutic effect is based87, arguing that this concept must be distinguished 
from 'excipient'. According to the list of reference terms in the European 
Pharmacopoeia, drawn up under the aegis of the Council of Europe, an excipient is an 
auxiliary substance generally therapeutically inert, and needed for the manufacture, 
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administration or conservation of the active ingredient. Its function is to act as a vector 
or carrier for the active ingredient, thereby contributing to certain properties of the 
product, such as its stability, its galenical form or its acceptability for the patient88. The 
Court basically adopted this Opinion, holding that a substance which does not have any 
therapeutic effect of its own and which is used to obtain a certain pharmaceutical form 
of a medicinal product is not covered by the concept of ‘active ingredient’, which, in 
turn, is used to define the term ‘product’ 89 . According to this interpretation, the 
excipient itself does not constitute an API.  
Having precluded the possibility of the excipient being an API, the question becomes 
whether it can be regarded as ‘combination of active ingredients’, i.e. whether the 
concept ‘combination of active ingredients’ requires that each of the components of this 
combination is an API with its own therapeutic effects, or the combination of a new 
excipient with a known API suffices, if this combination results in a new medicinal 
product in which the therapeutic effects of the API are defined and controlled by the 
additional substance (i.e. the excipient). In support of the first interpretation, one could 
argue that the distinction between these two expressions (APIs and combination of 
APIs) could be evidence that only APIs or combinations of two or more APIs making 
up a medicinal product come under the term ‘product’. The second interpretation can 
find ground on the Explanatory Memorandum for the proposal for a SPCR; it is stated 
there90 that all pharmaceutical research which may be patented, whether it concerns a 
new product, a new process for obtaining a new or known product, a new application 
of a product or a new combination of substances containing a new or known product, 
must be encouraged.  According to the first interpretation, where one of the components 
of the combination does not itself have any therapeutic effect, the grant of the SPC 
would not be possible, whereas according to the second one such a grant would be 
possible.  
In MIT case the Court had to choose between those two interpretations91. The AG took 
the view that, where the effective treatment of certain illnesses requires an active 
ingredient to be combined with a substance which, whilst not having any 
                                                          
88 Advocate General’s Opinion in C-431/04 at [11]. 
89 C-431/04 at [25]. 
90 Explanatory Memorandum (n 63) at [29]. 
91 Advocate General’s Opinion in C-431/04 at [27]-[30]. 
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pharmacological properties of its own, allows the biologically active substance 
effectively to release its therapeutic effects, such a combination must fall within the 
scope of 'combination of active ingredients of a medicinal product' within the meaning 
of Article 1(b) of the SPCR92. According to his opinion, it is the necessity of the 
excipient for ensuring the therapeutic efficacy of the active ingredient that must be the 
determining factor in ascertaining whether a combination of these two substances is 
covered by 'combination of active ingredients of a medicinal product'. Unlike the AG, 
the Court adopted a purely literal interpretation of Article 1(b), concluding that the 
alliance of an API with a substance which does have therapeutic effects of its own 
cannot give rise to a ‘combination of active ingredients’93. Again the Court justified its 
judgment, inter alia, on the basis of the strict interpretation given to the term ‘product’ 
in the Explanatory Memorandum94. The recent judgment in Forsgren case points out 
that this founding is not altered by the fact that the API is covalently bound to other 
APIs which are part of the medicinal product95. 
When both of the above questions were addressed later in GSK case to the CJEU, the 
latter ruled by reasoned order, since the issues at stake were clarified by its judgment 
in MIT96. Aside from the above core judgments, there are also earlier decisions which 
dealt with this matter in the same manner, i.e. stating that the concept of ‘product’ 
referred to in Article 1(b) SPCR must be interpreted strictly to mean ‘active substance’ 
or ‘active ingredient’97. More concretely, the Court in BASF case held that a greater 
purity of an API does not give rise to a different ‘product’98. In Farmitalia, the Court 
stated that minor variations do not make the ‘product’ different99. Furthermore, in 
Yissum100, the Court stated that in a case where a basic patent protects a second medical 
use of an API, that use does not form an integral part of the definition of the product101. 
                                                          
92 Advocate General’s Opinion in C-431/04 at [40] et seq. 
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The Court, further, clarified in Pharmacia Italia that it is irrelevant in this respect 
whether the product subject to SPC protection is for use in humans or in animals102.  
It should be noted though, that, as opposed to the two latter judgments, according to the 
more recent judgment in Neurim case - which was not handed down on the question of 
the interpretation of Article 1(b) SPCR, but rather on Article 3(d) SPCR - the SPC grant 
is possible for second medical uses103.  It has been supported that this broader definition 
of the term ‘product’ is most likely in line with the definition under Article 1(b) 
SPCR104. This opinion, which finds ground on Recital 14 PPR, which under Recital 17 
PPR also has to be applied to the interpretation of SPCR, indicates that the strict 
definition of the term ‘product’ has to be broadened for second medical indications105.  
2. Subject to a marketing authorization procedure 
Article 2 SPCR seeks to determine in a general manner which products may be the 
subject of a SPC. Under this Article any product protected by a patent in the territory 
of a Member State and subject to a marketing authorization (‘MA’) procedure may be 
the subject of a SPC. It is specified that the MA concerned is that provided for in 
Directives legislating the issue of MA (‘MAD), i.e. Directives 2001/83/EC106  and 
2001/82/EC 107 , thereby making it clear that the SPCR applies only to medicinal 
products for human or veterinary use108. It is also clarified that the word ‘market’ in 
Article 2 SPCR does not refer to the market of a Member State, but to the Community 
market as another interpretation would deprive Article 2 of any raison d’être109. 
                                                          
102 C-31/03 at [20]. 
103 C-130/11 at [25]. 
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for non-medicinal purposes), this situation would seem to be at cross-purposes with the objectives of 
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The question that arises at this point is whether MA granted before entry into effect 
MAD could be considered as MA within the meaning of the above Article. The CJEU 
answered this question in the negative. More concretely, the CJEU ruled in Synthon 
that a product, which was placed on the market in the Community as a medicinal 
product for human use before obtaining a MA in accordance with the MAD and, in 
particular, without undergoing safety and efficacy testing, is not within the scope of the 
SPCR, and may not, therefore, be the subject of a SPC110. The Court justified its 
decision by stating that it would be contrary to the objective of offsetting the time taken 
to obtain a MA – which requires long and demanding testing of the safety and efficacy 
of the medicinal product concerned – if an SPC, which amounts to an extension of 
exclusivity, could be granted for a product which has already been sold on the 
Community market as a medicinal product before being subject to a MA procedure as 
laid down in MAD, including safety and efficacy testing111. In addition, the Court stated 
that issuing a SPC for a product which does not fall within the scope of the SPCR 
disregards the meaning of ‘product’ and thus, such a SPC is invalid pursuant to Article 
15 SPCR112. The same approach was followed by the Court in Generics113. Thus, it is 
clear that a SPC for a medicinal product is valid, only if the first MA in the EU is in 
line with Europe-wide regulatory rules, i.e. with the MAD114. 
IV. THE EXTENT OF THE PROTECTION GRANTED 
As mentioned above, supplementary protection is intended for the API or the 
combination of APIs of a medicinal product. The question, however, is how extensive 
that protection will be.  At first, it was proposed that the supplementary protection 
should have the same effect as a patent, i.e. include all medicinal use of the API. The 
Commission adopted a narrower protection though115. More concretely, pursuant to 
Article 4 SPCR, the protection conferred by a SPC does not extend to the scope of the 
patent as a whole, but it extends only to the product covered by the MA and for any use 
of the product authorized before the expiry of the SPC. As a result, protection under a 
                                                          
110 C-195/09 at [51]. 
111 C-195/09 at [46], [47]. 
112 C-195/09 at [53] et seq. 
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SPC is limited by116: (i) the scope of the basic patent, (ii) the uses authorized prior to 
the expiry of the basic patent, and (iii) the uses in the pharmaceutical field as defind by 
MAD. The delimitation of the subject protected by the SPC can be well understood in 
cases where a patent protects a series of products based on the same formula. In such 
cases, usually only some of these products are subsequently developed and possibly 
only one may be put on the market. Thus, the SPC will only protect the product covered 
by the MA and not all of the products protected by the patent117. A further example is 
GSK118case, where the CJEU stated that, where a patent protects an adjuvant as such, 
an SPC cannot be granted in respect of that adjuvant, since it cannot be regarded as a 
‘product’ within the meaning of Article 1(b) SPCR119. 
This delimitation of the subject matter gave rise to the issue of whether the SPC holder 
can oppose to a product comprising the API, which is protected by his SPC, with other 
APIs. Two reasoned orders relating both to disputes between Novartis v Actavis120 dealt 
with this matter. In essence, the Court had to decide between a regulatory approach, 
which limits the protection to the product covered by the MA121, and a patent law 
approach, which confers on the SPC the same rights as the basic patent122. Staying in 
line with its previous case-law123, the Court supported the second approach, holding 
that during the period in which the patent was valid, the patent holder could oppose, on 
the basis of his patent, all uses of his product and that the SPC granted in relation to 
that product would confer on the holder the same rights for all of its uses which were 
authorized before the expiry of the SPC124. As a result, if a SPC is granted for product 
A, the SPC holder has the right to launch infringement proceedings concerning a 
medicinal product containing A+B provided that this would have been possible under 
the basic patent125. 
The terms of this provision also gave rise to the question of whether the SPC can only 
be granted for the specific chemical form mentioned in the MA or whether the 
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protection conferred by the SPC can be broader, extending also to simple derivatives, 
salts or products of the product126. In Farmitalia127 the Court stated that if the SPC 
could protect only a specific API whereas the basic patent protects the specific API and 
its various derivatives, any competitor would be able, after the expiry of the basic 
patent, to obtain a MA for a derivative of the same API, formerly protected by the 
patent, enabling thus, medicinal products therapeutically equivalent to that protected by 
the SPC to compete with the latter128. As a result, the fundamental objective of the 
SPCR, which is to provide for sufficient protection to encourage research in the 
pharmaceutical field, could not be attained129. Besides, the Court stated that the SPC 
confers the same rights as those conferred by the basic patent, with the result that, where 
the basic patent covers an API and its various derivatives, the SPC confers the same 
protection130. Therefore, the Court concluded that, where a product in the form referred 
to in the MA is protected by a basic patent in force, the SPC is capable of covering the 
product, as a medicinal product, in any of the forms enjoying the protection of the basic 
patent131. 
A different aspect of the scope of protection concerns which actions are to constitute 
infringement and what restrictions are made concerning acts of infringement. Pursuant 
to Article 5 SPCR, the SPC confers the same rights as conferred by the basic patent and 
is subject to the same limitation and obligations. National patent law determine which 
actions constitute infringements, the possibilities of granting interlocutory prohibitions 
and the sanctions available to the patentee132. 
V. OBTAINING A SUPPLEMENTARY PROTECTION CERTIFICATE 
1. Conditions 
a. Introduction 
Having determined the products which may be the subject of a SPC, the SPCR sets out 
in Article 3 SPCR the conditions under which those products may be granted a SPC133 
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132 Domeij B., (n 54) 205; Cook T., (n 77) 141; Morze’ H./Hanna P., (n 84) 499. 
133 C-195/09 at [41]; C-130/11 at [20].  
19 
 
and which are the same for all Member States134. As the SPC is a national document, 
compliance with these conditions must be examined with respect to the Member State 
in which the SPC application is submitted and to the application date135. The first three 
conditions set out in Article 3 of the SPCR for the grant of an SPC concern the relevant 
product and require it to be protected by a basic patent in force, to have obtained a valid 
MA as a medicinal product, and to have not already been the subject of a SPC136, whilst, 
the fourth condition requires that this MA must be the first MA to place the product on 
the market as a medicinal product.  
b. Basic patent in force [Articles 1(c), 3(a)] 
Having confirmed the existence of a product, it should be now examined whether it is 
covered by a basic patent in force in the Member State in which the SPC application is 
submitted. A ‘basic patent’ is defined in the SPCR as a patent which protects a product, 
a process to obtain a product or an application of a product, and which is designated by 
its holder for the purpose of the procedure for grant of a SPC137. It is supported that this 
list of ‘basic patent’ categories is not enumerative, but it should be rather treated as 
illustrative, since the proposal for SPCR does not provide for any exclusion from SPC 
protection and all pharmaceutical research should be encouraged without 
discrimination, as the Explanatory Memorandum points out138. A basic patent may 
either be a national patent or a European patent. A product may be protected by different 
patents, e.g. a product patent or a process patent to obtain such product139. The SPCR 
does not limit a patentee’s choice to select his ‘basic patent’ from a product, process or 
use patent for SPC protection. However, a patentee must select one patent, if there is a 
choice between different patents140. It is not clear whether the patentee has an open 
choice, i.e. whether he can select whichever patent other than the first or earliest patent 
claiming that product, but it is supported that such a choice is not precluded141.  
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It comes from the above that the SPC is closely connected with the patent and 
concomitantly, with its claims which, as mentioned above, determine the extent of the 
patent protection. That being so, the question of whether a SPC can be granted in respect 
of APIs which are not specified in the wording of the claims of the basic patent comes 
into play. The CJEU answered in the negative, and, although it did not foster R&D, it 
went for a uniform application of the SPCR throughout the EU142. More concretely, in 
Medeva143, the CJEU held that a SPC should not be granted when the APIs are not 
specified in the wording of the claims of the basic patent relied on in support of the SPC 
application144. Therefore, whether a product is protected by the basic patent within the 
meaning of Article 3(a) of the SPCR is determined by examining the patent claims to 
establish whether the APIs of the product are specified in the wording of the claims145.  
In Aventis146 , the Court clarified, by means of reasoned order due to its previous 
judgment in Medeva case, that a SPC should not be granted, if the API specified in the 
application is not the subject of any claim relating to that API alone, even though it is 
identified in the wording of the claims of the basic patent as an API forming part of a 
combination in conjunction with another API147.  Accordingly, if a patent claims a 
product comprising two APIs which are not specified alone in the patent application, a 
SPC cannot be granted based on such a patent for products having only one API148. 
Concomitantly, Aventis case further narrows the test applied in Medeva case: if the 
patent claims A+B, a SPC cannot be granted for just A149. Further, in Queensland 
case150 the Court clarified that, where the basic patent relates to the process by which a 
product is obtained, a SPC cannot be granted for a product other than that identified in 
the wording of the claims of that patent as the product deriving from that process.  
However, the above mentioned decisions did not clarify the crucial issue of the level of 
specification in the claims required to obtain a SPC for active ingredients151. A first 
insight into this black-box element was given by the Eli Lily case152. There the Court 
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held that it is not necessary for the API to be identified in the claims of the patent by a 
structural formula; a functional description in the claims of a patent issued by the 
European Patent Office (EPO) may suffice for identification purposes, on condition that 
the claims of the basic patent relate, ‘implicitly but necessarily and specifically’, to the 
API in question153. The formula ‘implicitly but necessarily and specifically’ seems to 
contain no further guidance on the appropriate level of specification in the claims154, 
and the onus of its correct interpretation of lies with the national courts155. 
c. Valid marketing authorization [Articles 2, 3(b)] 
A further condition for the grant of a SPC is the existence of a valid MA to place the 
product on the market in the Member State in which the SPC application is submitted 
as a medicinal product. As already mentioned, the MA must be valid at the time of 
filing the application for a SPC156. However a valid counter-argument is that a SPC has 
no legal effect whatsoever until it takes effect at the end of the lawful term of the basic 
patent and it should only be decisive whether from that time onwards the MA for the 
product in the country concerned is valid157. 
The question which arises is whether it is possible to obtain an SPC for an API or 
combination of APIs, where the MA submitted in support of the SPC application was 
not only for that API or combination of APIs, but also for other APIs. In Medeva158 and 
Georgetown I159 the Court answered in the affirmative, stating that a valid MA to place 
the product on the market can exist even where the MA relates to a medicinal product 
which also comprises, in addition to the patented API or in addition to the patented 
combination of APIs, in respect of which a SPC is applied for, one or more other 
APIs160. Therefore, the Court held that it should be possible to obtain a SPC for A on 
the basis of a MA for A+B161. By this interpretation of Article 3(b), manufacturers of 
medicinal products were permitted, in principle, to apply for a SPC for individual 
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patented APIs, even where those APIs have been placed on the market together with 
other unpatented APIs in a combination medicinal product 162 . In this respect, as 
opposed to its restrictive approach on Article 3(a) SPCR, the Court chose a broad 
interpretation of Article 3(b) SPCR163. 
Another issue is whether a SPC can be granted in respect of an API whose therapeutic 
effect does not fall within the therapeutic indications covered by the wording of the 
MA. In Forsgren the CJEU stated that Article 4 SPCR implies that a use of a product 
which has not been authorized as a medicinal product may not be covered by a SPC. 
Therefore, the Court concluded that an API whose therapeutic effects do not fall within 
the therapeutic indications for which a MA was granted may not give rise to the grant 
of a SPC164. 
d. No previous SPC granted [Article 3(c)] 
Article 3(c) SPCR requires that the product has not already been the subject of a SPC 
in the Member State where the SPC application is submitted.  
The question which comes into consideration is whether, where a medicinal product is 
covered by several basic patents in force, the grant of a SPC to each holder of a basic 
patent is precluded. As stated above, pursuant to Article 1(c) SPCR, a patentee must 
select a basic patent covering the product on which a SPC application is based and 
cannot obtain two SPCs for the same product. However, several SPCs each relating to 
distinct products covered by different MAs but all say in a related class covered by the 
same patent, are possible165. That means that, if a product involves more than one 
inventive concept that results in patents owned by separate legal entities, each entity 
should be entitled to SPC protection, because each entity should be entitled to designate 
a patent as the basic patent for a SPC application166. If only one SPC is to be granted 
between two patentees, it is unclear to whom it should be awarded: to the party first to 
file its SPC application or to the party whose SPC happens to be the first to be 
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granted167. Besides, the SPCR does not explicitly provide for the ‘first-to-file’ principle 
with regards to SPC applications 168 . This approach was adopted by the CJEU in 
Biogen169 case, where various patent holders had applied for SPCs simultaneously; that 
is, all applications were pending. The Court there, namely, held that, where a product 
is protected by a number of basic patents in force, which may belong to a number of 
patent holders, each of those patents may be designated for the purpose of the procedure 
for the grant of a SPC170.  
Resolved though it may seemed, the issue arose again, when the PPR came into force, 
the provisions of which referred to this matter. More concretely, under Article 3(2) of 
the PPR where two or more applications concerning the same product and emanating 
from two or more holders of different patents are pending, one certificate for this 
product may be issued to each of these holders. Further, according to the Recital 17 of 
the PPR the detailed rules in Articles 3(2) of the PPR are also valid, mutatis mutandis, 
for the interpretation of Article 3 of the SPCR.  
Despite the new provisions, the CJEU stayed in line with its previous case-law. In AHP 
Manufacturing171, the Court held that the holder of a basic patent may be granted a SPC 
for a product for which, at the time the SPC application is submitted, one or more SPCs 
have already been granted to one or more holders of one or more other basic patents. 
This founding is not altered by the fact that the application for SPCs were not ‘pending’ 
in the AHP Manufacturing case, within the meaning of Article 3(2) PPR, like it was the 
case in the Biogen case, but the SPC application was filed at a time when the SPCs 
relating to the other patents had already been granted and were no longer pending. The 
simultaneity of the applications was namely not considered to be essential for the grant 
of a SPC, since the strict textual interpretation of the word ‘pending’ would effectively 
deprive the latter applicant of the benefit provided for by SPCs which would run 
contrary to the fundamental objective of the SPCR to ensure sufficient protection and 
to encourage pharmaceutical research172. In this context, the Court stated that the SPCR 
seeks also to confer supplementary protection on the holders of national or European 
                                                          
167 Morze’ H./Hanna P., (n 84) 491. 
168 Morze’ H./Hanna P., (n 84) 492. 
169 C-181/95. 
170 C-181/95 at [28]. 
171 C-482/07. 
172 Gassner U.M., (n 77) 51; C-482/07 at [30]. 
24 
 
patents without instituting any preferential ranking amongst them173. Moreover, the 
CJEU stated that a literal interpretation of Article 3(2) PPR would lead to a situation 
where the grant of an SPC could depend on an event which was uncertain and, as a rule, 
outside the control of the applicant, namely the date of the office’s decision on the grant 
of one or more SPCs174. Such a solution would thus, risk considerably reducing the 
possibility, provided for in Article 3(2) of PPR, for two or more holders of different 
patents for the same product to obtain an SPC for that product175. 
To sum up, the rule is that where a product is protected by a number of basic patents in 
force, each of those patents may be designated for the purpose of the procedure for the 
grant of a SPC, but only one SPC may be granted for each basic patent. Concomitantly, 
an applicant may be granted a SPC, if at time of application a third patent proprietor 
has already obtained a SPC or has applied for a SPC for the same product. As a 
consequence, the scope of application of Article 3(c) SPCR is restricted to cases where 
the same applicant has already received a SPC176. This scope becomes even narrower 
by the judgment in Neurim177 case.  There the Court noted that its decision does not 
depend upon the identity of the proprietors of the MAs178, patents or SPC application, 
which suggests that it should be possible for the same company to obtain SPCs for 
different medical uses of the same API, on condition that they are the subject of 
different patents179. Therefore, a previous SPC is considered to exist, precluding thus 
the grant of another SPC, where the same applicant has already received a SPC for the 
same medical use of the same API. 
The above rule though gave rise to some ambiguities in its applicability to combination 
products. More concretely, when it comes to combination products, the same patent 
may be regarded as protecting a number of products, thus raising a different question 
from those referred in, inter alia, the cases which gave rise to the decisions in Biogen 
and AHP Manufacturing, namely whether such a patent may permit its holder to obtain 
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more than one SPC180. The CJEU clarified this issue in Actavis181 and Georgetown II182 
case.  
In Actavis, the CJEU stated it is possible, in principle, on the basis of a patent which 
protects several different ‘products’, to obtain several SPCs in relation to each of those 
different products, provided, inter alia, that each of those products is ‘protected’ as such 
by that ‘basic patent’ and is contained in a medicinal product with an MA183. The Court 
noted though, that it cannot be accepted that the holder of a basic patent in force may 
obtain a new SPC, potentially for a longer period of protection, each time he places on 
the market in a Member State a medicinal product containing, on the one hand, the 
principle API, protected as such by the holder’s basic patent, and, on the other, another 
API which is not protected as such by that patent184. The Court added that the SPC is 
designed simply to re-establish a sufficient period of effective protection of the basic 
patent which is intended to compensate for the delay to the commercial exploitation of 
his invention by reason of the time which has elapsed between the date on which the 
application for the patent was filed and the date on which the first MA in the EU was 
granted185. The Court concluded that, where a patent protecting a medicinal product 
containing an API has already enabled its holder to obtain a SPC relating to that API, a 
second SPC relating to a combination of that API with other APIs cannot be issued on 
the basis of the same patent186. That is, a SPC granted for ingredient A, precludes the 
grant of a second SPC for the combination of ingredients A+B 
As opposed to this judgment where the patented medicinal product consisted of an API, 
the Court ruled in Georgetown II on a case where the patented medicinal product 
consisted of a combination of several APIs. The CJEU held that, where a patent 
protecting a medicinal product consisting of a combination of several APIs has already 
enabled its holder to obtain a SPC relating to that combination of APIs, a second SPC 
relating to one of those APIs  may be issued on the basis of the same patent, provided 
that that API, individually, is also protected as such by that patent187. On the contrary, 
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the AG did not distinguish this case from Actavis; in his Opinion, he did not explicitly 
comment on the number of SPCs allowed per patent under Article 3(c) SPCR and 
proceeded from the assumption of a preclusion of more than one SPC188.  That is, a 
SPC granted for the combination of ingredients A+B, does not preclude the grant of a 
second SPC for ingredient A as such. 
Although the above decisions clarify some issues, they still leave some queries 
unanswered189. For example, in Georgetown II, the second to fifth questions were not 
answered190, and thus it remained unclear whether a SPC can be granted for a product 
protected by a basic patent, if an SPC has already been granted for another product 
protected by the same basic patent, but where the applicant surrenders the latter SPC, 
with a view to obtaining a new SPC on the basis of the same basic patent. 
e. First marketing authorization [Article 3(d)] 
Article 3(d) of SPCR provides that a SPC for a product may be applied for only on the 
basis of the first MA to place that product on the market of the Member State in which 
the SPC application is submitted as a medicinal product for human use or as a veterinary 
medicinal product. It follows directly from a purely literal interpretation of this 
provision that any further MA to place that product on the market as a medicinal product 
is to be regarded as a later MA, on the basis of which — according to the wording of 
Article 3(d) — an application for a new SPC cannot be made191. This approach was 
confirmed by the judgments in Yissum192, Pharmacia Italia193 and Medeva194 cases. 
However, the CJEU, by handing down in the more recent case Neurim195 , eased the 
limitation imposed on applicants based on the existence of earlier MAs for the same 
API or combination of APIs.  There the Court adopted a new legal approach as to what 
constitutes ‘a first MA’, paving thus, the way for new SPC grants notwithstanding the 
existence of earlier MAs for the same API196. More concretely, the patent holder in this 
case was seeking to obtain a SPC for the use of a API with a therapeutic application 
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(treating human sleep disorders), while there was an earlier MA for the use of the same 
API with another therapeutic application (regulating the seasonal breeding activity of 
sheep)197. The Court noted that  the placement on the market of a new medicinal product 
commercially exploiting the new therapeutic application of the same API, as protected 
by the new patent, may enable its proprietor to obtain a SPC, the scope of which, in any 
event, could cover, not the API, but only the new use of that product198. The CJEU 
reached thus, the conclusion that the mere existence of an earlier MA obtained for a 
veterinary medicinal product does not preclude the grant of a SPC for a different 
application of the same product for which a MA has been granted, provided that the 
application is within the limits of the protection conferred by the basic patent relied 
upon for the purposes of the application for the SPC199.  
The approach adopted in Neurim, to grant SPCs for second medical indications in 
certain cases via a restrictive interpretation of Article 3(d) SPCR, means that there is 
no longer a uniform interpretation of the term ‘product’ in the SPCR200. Whereas in 
case-law on Article 1(b) SPCR the term ‘product’ is defined in relation to the substance, 
the interpretation in Article 3(d) SPCR relates to the basic patent201. Thus, there are de 
facto two juxtaposed definitions of the term ‘product’ as, according to previous case-
law of the CJEU on Article 1(b) SPCR, SPC are precluded generally for uses of a known 
API202, whether for other species203 or as a second medical indication204. Such an 
approach is not in line with the logic of the SPCR, according to which Article 1 SPCR 
contains the definitions of the core terms of the SPCR that are to be applied in the 
subsequent provisions205. It remains unclear whether Neurim is compatible with the 
previous interpretation of Article 1(b) SPCR as regards second medical indications, 
since this question was not addressed in the judgment206. It is also doubtful whether 
such an expansion of the term ‘product’ beyond a narrow interpretation of Article 3(d) 
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SPCR is compatible with the logic of the SPCR or whether it does in fact concern an 
interpretation issue under Article 1(b) SPCR207. 
2. The application procedure 
The SPC is granted at the request of the holder of a national or European patent208. Even 
though SPCs are subject to European and not national law, and thus, are regulated at 
the EU level, applications for SPCs must be filed and approved on a country-by-country 
basis209. More concretely, competent authority for the filing of the application for a SPC 
is the industrial property office of the Member State which granted the basic patent or 
on whose behalf it was granted and in which the MA to place the product on the market 
was obtained210. The application shall be lodged within six months of the date on which 
the MA to place the product on the market in the State concerned as a medicinal product 
was granted211. If, however, the patent is by the issuing of the MA not granted, the six-
month term will start as of granting of the patent212. Generally, the sixth-month-period 
takes particular account of the interests involved: those of the patent holder who, after 
having applied for the SPC, may, if he so wishes, forego the SPC, if his product proves 
to be unsuccessful on the market; and those of third parties who have interest in 
knowing as early as possible whether or not the product concerned will be protected by 
a SPC once the basic patent has expired213.  
The applicant must provide the national patent office with some documents 214.  Apart 
from the request itself, a copy of the first MA to place the product on the market in the 
State concerned is required as this enables the product to be identified. If this MA is not 
also the first MA to place the product on the Community market, a copy of the latter 
also has to be attached, since the duration will be calculated, in all Member States in 
which a SPC is applied for, by reference to this criterion alone. Information enabling 
the basic patent to be identified must also be provided. The need to provide with a copy 
of the first MA was moderated in Biogen215 case. More concretely, the applicant of the 
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SPC (owner of the basic patent and licensor) and the holder of the MA (licensee) were 
different persons, and the owner of the basic patent was unable to provide such copy. 
Staying in line with its previous case-law216, the Court held that in this case a SPC 
application must not be refused on that ground alone and that the mere cooperation 
among administrations would suffice217.  
Where the SPC application and the product to which it relates meet the conditions laid 
down in the SPCR, the competent authority grants the SPC; otherwise the application 
is rejected218. A notification of the grant or the rejection of the SPC is published in an 
official bulletin 219 . This is to ensure that third parties are informed as soon as 
possible 220 . This decision is open to administrative appeals pursuant to national 
legislation221. 
VI. TERM OF SPC PROTECTION 
1. Normal term 
Under the TRIPS agreement222, patent rights must be “enjoyable without discrimination 
as to […] the field of technology […]”.  Before the SPCR came into force though, the 
practice imposed heavy penalties on pharmaceutical research, which was therefore 
discriminated as compared with other technological sectors 223 . In order to grant 
adequate effective protection for medicinal products equivalent to that enjoyed by other 
technological sectors, the SPCR includes provisions regulating the duration of the 
exclusive rights enjoyed by the holder of both a patent and a SPC.  
More concretely, under Article 13 SPCR the duration of the SPC is subject to two 
limitations224. The first limitation constitutes a standard deduction of five years from 
the time lost between patent filing and the date of the first MA in the Community225. It 
should be noted that, unlike Article 3(b), (d) SPCR which refers, in respect of the SPC 
grant, to a first MA issued in the Member State in which the SPC application is 
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submitted, Article 13(1) SPCR refers, in respect of the SPC duration, to the first MA in 
the Community226. Reason for this is that the duration of the SPC covering one and the 
same medicinal product must be the same throughout the Community in order to 
facilitate the functioning of a genuine Community market227. In its recent reasoned 
order in Merck Canada the Court stated that the words ‘first authorization to place a 
product on the market in the Community’ in Article 13(1) SPCR refer to the first MA 
issued in any of the Member States and not to the first MA in the Member State in 
which the SPC application is submitted, as only that interpretation ensures that the SPC 
will expire at the same time in all of the Member States in which the certificate was 
granted228. Second limitation is an upper limit of five years for the duration of the 
SPC229. The SPCR only defines the maximum period of the SPC duration, and may be 
less than this maximum, if the SPC holder opts to pay fees for a lesser period230.  
As a result from the upper limit for the SPC duration at 5 years, there is no benefit in 
applying for a SPC, where less than five (5) years have elapsed between the date of 
patent filing and the date of the respective MA, since the resulting SPC would have a 
nominally negative term 231 . This may be well understood through the following 
hypothetical example232: A company files a European patent application in 1990, which 
is subsequently granted. One would expect the patent to expire in 2010. In 1997 the 
first MA in the Community is granted. Normally, the company would expect a SPC to 
provide protection until 2012 (2010+[1997-1990]-5 = 2012). However, if the first MA 
in the Community was first obtained in 1992, there would be no SPC protection. 
Further, in setting the upper limit for the duration of the SPC at 5 years, the SPCR 
penalizes medicinal products with a development time exceeding 10 years by awarding 
shorter effective patent lives to those products233. While a product with a development 
phase of 10 years will enjoy only 15 years of effective patent life234, the product whose 
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development takes 12 years, will only enjoy 13 years of effective patent life235. This 
reflects a bias against products for the treatment of chronic diseases where longer 
testing periods and thus longer development times are required236.  
Since determining factor for the SPC duration is the first MA to place a medicinal 
product on the market in the Community, the question of whether a MA issued by a 
State of the EEA is regarded as the first MA in the Community came into play. The 
CJEU answered in the affirmative by a series of decisions. More concretely, in Novartis 
and Others237 the CJEU held that a MA issued by Switzerland (which did not ratify the 
SPCR) and automatically recognized by Liechtenstein is the first MA to place the 
product in one of the States of the EEA and thus, it constitutes the first MA within the 
meaning of Article 13 SPCR which should be taken into consideration for the purposes 
of calculating the duration of the SPC238. In strict legal terms, the SPCR does not apply 
in Switzerland and a first MA in Switzerland is not a MA in the Community. However, 
the automatic applicability of the MA in Liechtenstein means that the product 
concerned is available in part of the EEA. Staying in line with this decision, the CJEU 
issued a reasoned order in Astrazeneca239. There the Court held that, in the context of 
the EEA, under Article 13(1) SPCR a MA issued for a medicinal product by a State of 
the EEA must be regarded as the first MA to place that medicinal product on the market 
in the EEA, where that MA predates MAs issued for the same medicinal product, either 
by the European Medicines Agency (‘EMA’), or by the competent authorities of EU 
Member States240.  
A further question arising relates to the date in which the MA to place a medicinal 
product on the market in the Community takes effect. The UK IPO, which dealt with 
this question, concluded that  a MA to place a medicinal product on the market in the 
Community granted according to the relevant European legislation, takes effect not on 
the date of decision by the European Commission, but rather, on the date that this 
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decision is notified to the applicant for the MA. Thus, the calculation of the duration of 
an SPC based upon such a European MA should take account of the date of notification 
of the decision by the European Commission to grant the relevant MA and not the date 
of the decision itself241. 
To sum up, the term of SPC protection should be calculated by reference to the first 
MA to place the medicinal product on the market in the Community, i.e. in a Member 
State of the EU or of the EEA, thereby avoiding different terms in the Member States242. 
In any case, the upper limit for the effective patent life of a product – that is the time 
period between the first MA in the EU or EEA and the date of expiry of the SPC – is 
15 years243, after which the medicinal product enters the public domain244. 
2. Extended term 
Under Article 13(3) SPCR a SPC can be extended by an additional half year to a 
maximum of 5 ½ years, if it covers a human medicinal product, and data from clinical 
trials conducted based on a Paediatric Investment Plan (‘PIP’), along with – where 
necessary - proof of possession of MA to place the product on the market of all Member 
States, have been submitted pursuant to Article 36 PUR. Such an extension may occur 
only once. The application for an extension of the duration may be made either when 
lodging the application for a SPC or when the application for the SPC is pending245. If 
the SPC is already granted, the application for the extension of its duration shall be 
lodged not later than two years before its expiry 246 .The period of the paediatric 
extension starts to run from the date determined by deducting from the patent expiry 
date the difference between five years and the duration of the period which elapsed 
between lodging the patent application and obtaining the first MA247. As a result from 
this provision, a SPC of negative duration may be attractive for a patent proprietor, 
since a paediatric extension is potentially available, where a MA application includes 
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the results of all studies conducted in compliance with a PIP that has been agreed with 
the EMA248.  
This gave rise to the issue whether a paediatric extension of a SPC could be granted in 
a situation where the SPC would have a negative term, i.e. it would nominally expire 
before it took effect at the end of the term of the patent upon which it was based249. The 
CJEU dealt with this issue in Merck Sharp250. At first, the Court stated that nothing in 
the wording of the provision of Article 13(1) or in any other provision of the SPCR 
suggests that a SPC of negative duration is necessarily precluded 251 . The Court 
continued, stating that, if a SPC was refused for having a negative or zero duration, the 
aim of the paediatric extension - which is to reward the evaluation of paediatric effects 
of the medicinal product concerned - would be jeopardized252. Thus, while a SPC of 
negative or zero duration serves no purpose of itself, the fact remains that such an SPC 
may be of use to the holder of the basic patent wishing to obtain the paediatric 
extension253. It has been supported that the Merck judgment deserves to be approved, 
since, by holding that an application for an extension of six (6) months can be filed, 
even if the SPC duration is negative or zero254, it may support the development and the 
accessibility of medicines for children255. Moreover, by adopting this approach the 
undesirable situation of potential applicants for a SPC deliberately delaying the grant 
of a MA in order to obtain a positive term is avoided256. 
Further problems relate to Article 8(1)(d) SPCR which establishes the necessary points 
to be included in an application for an extension of the SPC duration. A first issue 
concerns Article 8(1)(d)(i) SPCR and is that PUR fails to specify the means through 
which the applicant might demonstrate compliance with an agreed completed PIP. It 
has been supported that, since Community legislation has not drawn up a closed list of 
means whereby the applicant may prove compliance, the means available for the 
applicant to evidence the existence of this requisite will depend on the reliability and 
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probative efficacy of the information it contributes257. Another issue relates to Article 
8(1)(d)(ii) SPCR and is what constitutes “proof of possession of authorisations to place 
the product on the market of all Member States”. At the Paediatric Forum, 
pharmaceutical innovators proposed that a statement by the applicant indicating that it 
was prosecuting the MA in all Member States should be considered as valid proof258. 
A further question lies in determining whether the MA are MA as such or if they should 
be qualified, in the sense of including the studies carried out to the agreed PIP. While 
the European Commission has supported the need for qualified authorisations, the 
opposite opinion has also been supported 259 . In any case, beyond any legal 
consideration, due to the requirement of MA in ‘all Member States’, inadequate 
operation of Member States’ medicines authorities will have a direct adverse impact 
beyond their territories, precluding applicants from obtaining their legitimate rights in 
the entire Internal Market260.  
3. End of protection  
a. Expiry  
Pursuant to Article 14 SPCR the SPC lapses at the end of its effective period, or if its 
holder surrenders it, or if the annual fee is not paid in time, or if the product covered by 
the SPC may no longer be marketed following the withdrawal of the MA. In the latter 
case, the authority, which is competent for granting the SPC, may decide on its lapse 
either of its own motion or at the request of a third party261. The SPC efficacy may be 
restored, if the decision of invalidity of the MA is eventually reversed262.  
b. Invalidity 
Although issued SPCs are given the presumption of validity, they are not immune from 
invalidation. Pursuant to Article 15 SPCR, a claim of invalidity can be brought by any 
person. Invalidity can result from the following reasons: if the SPC was granted despite 
the non fulfilment of the respective legal prerequisites, or the basic patent has lapsed 
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before its lawful term expires, or the basic patent is revoked or limited to the extent that 
the product for which the certificate was granted would no longer be protected by the 
claims of the basic patent or, after the basic patent has expired, grounds for revocation 
exist which would have justified such revocation or limitation.  
It should be noted that Article 2 SPCR is not included in the above list of grounds on 
which a SPC is deemed to be invalid. Since it is not included in that list, the question 
of whether a SPC issued for a product outside the scope of the SPCR is invalid came 
into play. In Synthon263 the CJEU answered in the affirmative. More concretely, the 
Court stated that, even if it is not possible to infer from the wording or the origin of 
Article 15(1) SPCR that the list of grounds of invalidity of an SPC set out therein is not 
exhaustive, the infringement of an article of SPCR not referred to in Article 15(1) can 
render an SPC invalid owing to the connection between the provision in question and 
Article 3 SPCR264. The Court noted that the concept of ‘product’ in Article 3 SPCR 
refers necessarily to a product within the scope of the SPCR, as defined in Article 2 
thereof, and thus, issuing a SPC for a product outside the scope of the SPCR disregards 
the meaning of ‘product’265. Therefore, a SPC granted for a product outside the scope 
of SPCR, as that scope is defined in Article 2 SPCR, is invalid266. 
VII. TRANSITIONAL PROVISIONS 
According to the legal theory, the transitional provisions of a legislative act regulate the 
applicability of its rules to facts that have occurred before its entry into force or to 
pending legal actions267. Likewise, the transitional provisions of the SPCR set out the 
conditions for obtaining a SPC for a product, where, at the date of entry into force of 
the SPCR on the territory of a Member State, the product had already been placed on 
the relevant national market as a medicinal product268. The SPCR contains 3 groups of 
transitional provisions269: on its initial entry into force in Article 19, on accession of 
new EU Member States in Article 20, and on the existing national regimes for extended 
patent protection in Articles 21 and 13(4). More concretely, the transitional provisions 
                                                          
263 C-195/09. 
264 C-195/09 at [55]. 
265 C-195/09 at [56]. 
266 C-195/09 at [57]. 
267 Batakliev D., Supplementary Protection Certificates in Europe – Transitional Regime, 2013, 752. 
268 Batakliev D., (n 267) 750-751. 
269 Batakliev D., (n 267) 751. 
36 
 
of Article 20 SPCR function in two ways270: on the one hand, they extend the scope of 
the new regime to products for which MA had been issued before the initial entry into 
force of the SPCR or before its entry into force for the newly acceding Member States, 
and on the other hand, the transitional regime only applies to products marketed as 
medicinal products after a certain date. 
A question that came into consideration was whether a valid MA within the meaning 
of Article 3(b) SPCR is still required, even though not included in the transitional 
provisions. In Yamanouchi Pharmaceutical271, it was discussed whether the transitional 
provisions272 derogate from the general requirements273 regarding the grant of a SPC274. 
The Court held that a SPC can be granted under the transitional provisions only where 
the conditions set out in the general requirements of Article 3 SPCR are also fulfilled275. 
As the Court underlined, this approach is in line with the wording of these general 
requirements (the SPC ‘shall be granted’) and the transitional provisions (‘may be 
granted’), which makes clear that the latter provisions do not in any way preclude the 
requirements set out in the former provisions276. Besides, it is the MA referred to in the 
general requirements of Article 3 SPCR which confers entitlement to the SPC, since 
the protection extends only to the product covered by the MA in respect of the 
corresponding medicinal product277. The question in the mentioned case derived from 
the fact that the condition of a ‘valid authorization’ was not included in the transitional 
provisions of the pSPCR. This is also the case in the current SPCR. However, the phrase 
“without prejudice to the other provisions of this Regulation” at the beginning of the 
transitional provisions 278  of the current SPCR has probably made clear that the 
transitional provisions only complement the general requirements and do not replace 
them. 
In addition, the fact that for different Member States the transitional provisions have 
varying requirements as to the date of issue of the first MA has raised the question of 
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their compliance with the principle of equality of treatment under Community law and 
their validity. In Hässle the CJEU stated that the setting of different relevant dates for 
different Member States appears to be justified insofar as each of those dates reflects 
the assessment made by each Member State in the light, in particular, of its health 
system, the organisation and financing of which varies from one Member State to the 
next, confirming thus the validity of the transitional provisions and their conformity 
with the principles of Community law279. 
Further issues arose relating to the applicability of the transitional provisions of the 
SPCR. In Kirin Amgen280 it was discussed whether the holder of a European patent for 
a medicinal product can apply with the competent national (Lithuanian) authorities for 
the grant of a SPC on the basis of its Community MA under the transitional provisions 
of the SPCR. There was a transitional provision which was specifically referring to 
Lithuania, stating that a SPC shall be granted, if, amongst others, the first MA was 
national281.  Having pointed out that the transitional provisions had been specifically 
negotiate and they should be interpreted narrowly, the Court held that the above 
provision was not applicable, because the above requirement was not fulfilled, since 
the MA at issue was a Community and not a national one282. Furthermore, the Court 
stated that, although the Community MA (granted on 08.06.2001) entered into force in 
Lithuania on 1 May 2004, i.e. when Lithuania accessed the EU, the patent holder cannot 
waive the time limit283 for the lodge of the application for a SPC, since the entry into 
force of the Community MA cannot be equated with the date on which the MA was 
granted under Article 3(b) 284 . Therefore, the relevant date for assessment of the 
applicability of the transitional provisions is the date of the issue of the European MA 
and not its entry into force, whereas the fact that the European MA comes into force on 
the territory of a state at the time of its accession is irrelevant.  
There are also cases where MA obtained outside the territory of the Community or the 
EEA become effective on these territories by virtue of bilateral agreements285 . In 
Novartis and Others, a regional agreement between Liechtenstein and Switzerland 
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provides that Swiss MA automatically become effective on the territory of 
Liechtenstein. Thus, the CJEU reached the conclusion that such Swiss MA with effect 
in Lichtenstein shall be considered as the first MA in the Community for the purposes 
of Article 13 SPCR286. 
All in all, as a derogation from the general rules and because of their limited scope of 
application only to products placed on the market as medicinal products before entry 
into force of the SPCR, the transitional provisions have always been interpreted strictly 
by the CJEU. Therefore, any attempt to use the transitional provisions as a means of 
avoiding the general requirements of Article 3 SPCR or circumventing the temporal or 
territorial conditions therein have always been denied287. 
D. CONCLUSIONS 
I. RECAPITULATE THE CORE CJEU’s FOUNDINGS 
 Neither can an excipient which changes the behavior of an API be considered 
itself as an API, nor can it give rise to a combination of APIs, which, in turn, 
are used to define the term ‘product’ under the SPCR (MIT, GSK, Forsgren). 
 The greater purity of an API (BASF) and minor variations (Farmitalia) do not 
make the product different, thus qualifying it for a grant of another SPC.  
 The second medical use does not make the product different, thus qualifying it 
for a grant of another SPC (Yissum, Pharmacia Italia) ≠ the mere existence of 
an earlier MA obtained for a veterinary medicinal product does not preclude the 
grant of a SPC for a different application of the same product for which a MA 
has been granted, provided that the application is within the limits of the 
protection conferred by the basic patent relied upon for the purposes of the 
application for the SPC (Neurim). 
 A SPC for a medicinal product is valid, only if the first MA in the Community 
is in line with the MAD (Synthon, Generics). 
 If a SPC is granted for product A, the SPC holder has the right to launch 
infringement proceedings concerning a medicinal product containing A+B 
provided that this would have been possible under the basic patent (Novartis v 
Actavis). 
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 The protection conferred by the SPC can extend to any of the forms enjoying 
the protection of the basic patent, e.g. to simple derivatives, salts, or products 
of the product (Farmitalia). 
 A SPC cannot be granted when the APIs are not specified alone – either by a 
structural or by a functional formula - in the wording of the claims of the basic 
patent relied on in support of the SPC application. That is, if the patent claims 
A+B, a SPC cannot be granted for just A. (Medeva, Aventis, Queensland, Eli 
Lily). 
 A valid MA to place the product on the market can exist even where the MA 
relates to a medicinal product which also comprises, in addition to the patented 
API or in addition to the patented combination of APIs, in respect of which a 
SPC is applied for, one or more other APIs. That is, if there is a MA for A+B, a 
SPC can be granted just for A (Medeva, Georgetown I). 
 An API, whose therapeutic effects do not fall within the therapeutic indications 
covered by the wording of the MA granted, may not give rise to the grant of a 
SPC (Forsgren). 
 The holder of a basic patent may be granted a SPC for a product for which, at 
the time the SPC application is submitted, one or more SPCs have already been 
granted to one or more holders of one or more other basic patents. (Biogen, AHP 
Manufacturing). 
 Where a patent protecting a medicinal product containing an API has already 
enabled its holder to obtain a SPC relating to that API, a second SPC relating to 
a combination of that API with other APIs cannot be issued on the basis of the 
same patent; that is, a SPC granted for ingredient A, precludes the grant of a 
second SPC for the combination of ingredients A+B (Actavis)  
 Where a patent protecting a medicinal product consisting of a combination of 
several APIs has already enabled its holder to obtain a SPC relating to that 
combination of APIs, a second SPC relating to one of those APIs  may be issued 
on the basis of the same patent, provided that that API, individually, is also 
protected as such by that patent; that is, a SPC granted for the combination of 
ingredients A+B, does not preclude the grant of a second SPC for ingredient A 
as such (Georgetown II). 
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 Where the applicant of the SPC and the holder of the MA are different persons, 
with the result that the former cannot provide the competent patent office with 
the copy of the MA, a SPC application must not be refused on that ground alone 
and the mere cooperation among administrations would suffice (Biogen). 
 The term of SPC protection should be calculated by reference to the first MA to 
place the medicinal product on the market in the Community, i.e. in a Member 
State of the EU or of the EEA, thereby avoiding different terms in the Member 
States (Astrazeneca, Merck Canada). Even where MA is obtained outside the 
territory of the Community or the EEA, it can still become effective on these 
territories by virtue of bilateral agreements (Novartis and Others). 
 A six-month paediatric extension of a SPC could be granted in a situation where 
the SPC would have a negative term, i.e. it would nominally expire before it 
took effect at the end of the term of the patent upon which it was based (Merck 
Sharp). 
 A SPC granted for a product outside the scope of SPCR, as that scope is defined 
in Article 2 SPCR, is invalid, although this Article is not included in the list of 
grounds of invalidity provided for in Article 15 SPCR (Synthon). 
 A SPC can be granted under the transitional provisions only where the 
conditions set out in the general requirements of Article 3 SPCR are also 
fulfilled (Yamanouchi Pharmaceutical). 
 The varying requirements as to the date of issue of the first MA between the 
Member States does not infringe the principle of equality of treatment under 
Community law (Hässle). 
 The transitional provisions had been specifically negotiate and they should be 
interpreted narrowly (Kirin Amgen). 
 
II. FINAL REMARKS 
Although economists sometimes debate whether the patent system is useful 
generally288, no one has ever seriously challenged its place for medicines289. Patents are 
an important way to ensure that the benefits of research are captured by the creator, 
whilst the SPC has proven an effective instrument in protecting innovation for 
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medicinal products. Nevertheless, the patent applications in Pharmaceuticals filed with 
the EPO dropped significantly during the last two years290. This may derive, inter alia, 
from the uncertainty which still surrounds the SPC regime291, although some valuable 
clarifications have been made by the CJEU. As the AG Trstenjak in Neurim case 
pointed out, there are two lines of case-law regarding SPCs, which are difficult to 
reconcile292: i) a line of case-law based upon the idea that the grant of a patent normally 
confirms the eligibility for protection with the result that it should also be possible to 
grant a SPC, such as Medeva, Georgetown I and AHP Manufacturing, and ii) a line of 
case-law where the CJEU takes a stricter interpretation as regards the conditions for 
obtaining a SPC, such as the judgments in Synthon and Generics.  
Another concern relating to the future interpretation of the SPC regime, aside from the 
legal uncertainty, is whether the CJEU strikes a fair balance between the various 
interests at stake in the pharmaceutical sector. According to AG Trstenjak, those 
interests include, on the one hand, the interests of the undertakings and institutions, 
some of which pursue very cost-intensive research in the pharmaceutical sector, and on 
the other hand, the interests of the producers of generic medicines who, as a 
consequence of the extension of the term of protection of the active ingredients under 
patent protection, are precluded from producing and marketing generic medicines293. 
The SPC regime is also intended in the interests of both patients and national healthcare 
systems to prevent old APIs from being brought onto the market in slightly modified 
form under the protection of SPCs, but without genuine innovation and thereby 
artificially driving up expenditure in the health sector294. 
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